Advertisement

Topics

"Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis" Drugs and Medication Database

04:14 EST 19th February 2019 | BioPortfolio

Here are the most relevant "Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis" Drugs and Medications that we have found in our database.

More Information about "Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis" on BioPortfolio

We have published hundreds of Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis news stories on BioPortfolio along with dozens of Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis Clinical Trials and PubMed Articles about Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis Companies in our database. You can also find out about relevant Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis Drugs and Medications on this site too.

Showing "Safety Efficacy AIN457 ccedil Patients With Posterior Panuveitis" Drugs and Medications, all 11

Possibly Relevant

Humira [a-s medication solutions]

These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection, for subcutaneous useInitial U.S. Approval: 2002

Humira [abbvie inc.]

These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA (adalimumab) injection, for subcutaneous useInitial U.S. Approval: 2002

Phocal apf [u.s.i.a. inc]

phocal™

Phocal phn [phocal therapy inc]

phocal™

Membraneblue [dutch ophthalmic research center (international) b.v.]

MembraneBlue™ 0.15% (trypan blue ophthalmic solution). These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%. MembraneBlue™ 0.15% (try

Azathioprine [mylan pharmaceuticals inc.]

Azathioprine [mylan institutional inc.]

NA

Azathioprine [aphena pharma solutions - tennessee, llc]

NA

Retisert [bausch & lomb incorporated]

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use Initial U.S. Approval: 19

Visionblue [d.o.r.c. dutch ophthalmic research center (international) b.v.]

VisionBlue® 0.06% Trypan blue Ophthalmic Solution. These highlights do not include all the information needed to use VISIONBLUE® 0.06% safely and effectively. see full prescribing information for VISIONBLUE® 0.06%. VisionBlue® (trypan blue ophthalmic

Yutiq [eyepoint pharmaceuticals us, inc]

These highlights do not include all the information needed to use YUTIQ safely and effectively. See full prescribing information for YUTIQ.YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injectionInitial U.S. Approval: 1963



Advertisement
Quick Search
Advertisement
Advertisement